Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

UBER Stock Looks Desperate Going Into Earnings, so Stay Clear for Now

By Alex Sirois, InvestorPlace Contributor
UBER stock could be in big trouble or on the cusp of great success but it's best to steer clear for the time being.

Bionano’s Technology Is Interesting, But Its Earnings Are Uninspiring

By Ian Bezek, InvestorPlace Contributor
Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals.

Throw in The Towel, Ocugen Stock is Not Coming Back

By Thomas Niel, InvestorPlace Contributor
Barring the slim chance it gets EUA in Canada, which admittedly could result in an outsized move higher? Expect OCGN stock to continue trending lower, eventually falling back to around 70 cents per share.

7 F-Rated Stocks to Avoid for the Rest of 2021

By Louis Navellier and the InvestorPlace Research Staff
In a churning market like this, you want to steer clear of stocks that are floundering. Here are sevens stocks to avoid today.

There’s Little That’s Attractive About Once-Hot Zomedica Stock… for Now

By Ian Cooper, InvestorPlace Contributor
Zomedica has become a slow-motion train wreck. ZOM stock investors should look for alternatives to the animal diagnostics firm.

Marin Software Stock Has Very Little To Offer as Its Meme Status Fades Away

By Larry Ramer, InvestorPlace Contributor
Marin's financial results are unimpressive and meme stocks are weakening, making MRIN stock unappealing at this time.

Covid-19 Vaccine Dose Delay Spells Even More Trouble for Novavax Stock

By David Moadel, InvestorPlace Contributor
Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress.

Investors Should Avoid High-Risk Atossa Therapeutics

By Larry Ramer, InvestorPlace Contributor
Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point.

Clover Stock Is Really Unlikely To Get Squeezed Again

By Thomas Niel, InvestorPlace Contributor
There's a reason why CLOV stock has been shorted heavily. With trading trends no longer your friend, there's little reason to dive in today.

GameStop Had a Great Run, But It’s Time to Sell

By Ian Bezek, InvestorPlace Contributor
GameStop had a remarkable run. But it's out of positive catalysts. Once the buzz dies down, GME stock will decline significantly.

Biogen: Does Aduhelm Make it the Next Dendreon?

By Dana Blankenhorn, InvestorPlace Contributor
Aduhelm was approved by the FDA, priced at $56,000/year, but it isn't a cure for Alzheimer's.

7 Overheated Stocks to Sell as Pandemic Concerns Rise

By Josh Enomoto, InvestorPlace Contributor
Although the market is firing on all cylinders again, it’s time to consider trimming risk exposure in these stocks to sell.

Don’t Buy Novavax Until Its Covid-19 Vaccine Wins FDA Approval

By Joel Baglole, InvestorPlace Contributor
Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days.

Sell ContextLogic Stock While You Can Before Paper Losses Worsen

By Chris Lau, InvestorPlace Contributor
Investors WISH they did not invest in the company as its outlook, setting the risk for a lower stock price ahead.

If You’re a Long-Term Investor, Steer Clear of Marin Software

By Muslim Farooque, InvestorPlace Contributor
Recent gains have masked Marin Software's outlook and weak business model. Steer clear of MRIN stock if you're a long-term investor.

Don’t Bet on DiDi Global Stock Yet

By Thomas Niel, InvestorPlace Contributor
As China's regulatory crackdown on Didi continues, the verdict on DIDI stock is crystal clear: stay away for now.

Overvalued Meta Materials Will Drop 84% to Cash Per Share Value

By Mark R. Hake, CFA
Wait for Meta Materials to drop to its cash per share or 84% lower. MMAT stock is not worth more than 56 cents per share, or $160 million in cash divided by 285 million shares outstanding.

AMC Stock Is Only for Fearless Investors

By Faizan Farooque, InvestorPlace Contributor
The future of AMC stock is inextricably linked to Reddit. But AMC needs more catalysts to ensure its long-term survival.

3 Reasons ContextLogic’s CFO Departure Is Bad News for WISH Stock

By Will Ashworth, InvestorPlace Contributor
ContextLogic CFO Rajat Bahri resigned from his position June 24. If you own WISH stock this is not good news. Here’s why I feel this way.
Load More Articles